Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Chief, Division of Urology and Urologic Oncology
Professor, Department of Surgical Oncology
Kidney, Bladder, and Prostate Cancer TRDG Member
American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member
Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.
I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.
When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.
As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.
Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.
At 43, Matt Lofland worked out regularly to stay fit and active. So when he noticed some back pain on his left side, he didn’t think much of it. “I figured I just twisted my back when I was running,” he recalled. But the pain persisted, along with numbness down his left leg.
Nobody had to convince Tim Leedy that it was important to get his PSA tested regularly. His father died of prostate cancer, so there was a family history of the disease. Fortunately, Tim had many more options than his father had when his PSA levels spiked in May 2010, and a biopsy revealed that 59-year old Tim also had prostate cancer.
Benjamin Jackson has always been proactive about his health. He's fit and in good shape and sees his doctor for annual check-ups. These typically include a prostate-specific antigen (PSA) blood test, which can indicate an increased risk of prostate cancer. In October 2010, Benjamin learned that while his PSA levels weren't necessarily high, they had been increasing slightly each year. His primary doctor referred Benjamin to a local hospital for a biopsy. When the results arrived, Benjamin was asked to come to the office to discuss the results.
Forty-five days. That's how long it took from the moment in February 2011 that Shirley Danner, who was 73, felt a lump on her side when she rolled over in bed to the day her cancerous kidney was removed at Fox Chase Cancer Center. "It all happened so fast," explains Shirley, who lives in Willow Street, Pennsylvania, about two hours from the Fox Chase campus.
In his construction-related job, Don Sechler is a can-do guy who solves problems all day long. But one problem he didn't expect to confront was a diagnosis of bladder cancer. "I'd always been healthy," says Don. "I knew nothing about bladder cancer, or cancer period. It doesn't run in my family. I pretty much thought it was never going to hit me. Then boom."
Dr. Kutikov has authored over 140 peer-reviewed publications. His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks. He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.
Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care. He is a co-founder of several ventures that strive to improve physician education and patient care.
In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.
As part of our work, we explore the role of zinc in development and progression of prostate malignancy. Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.
The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.
In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.
A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed
H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed
M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed
N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed
B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed
S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed
A. Kutikov, H. H. Woo, and J. W. Catto, “Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors,” European Urology, vol. 69, no. 2, pp. 183–185, Feb. 2016. PubMed
A. Kutikov, M. C. Smaldone, R. G. Uzzo, M. Haifler, G. Bratslavsky, and B. C. Leibovich, “Renal Mass Biopsy: Always, Sometimes, or Never?,” European Urology, vol. 70, no. 3, pp. 403–406, Sep. 2016. PubMed
E. R. Plimack, R. L. Dunbrack, T. A. Brennan, M. D. Andrake, Y. Zhou, I. G. Serebriiskii, M. Slifker, K. Alpaugh, E. Dulaimi, N. Palma, J. Hoffman-Censits, M. Bilusic, Y.-N. Wong, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, D. J. McConkey, V. A. Miller, E. A. Golemis, and E. A. Ross, “Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer,” European Urology, vol. 68, no. 6, pp. 959–967, Dec. 2015. PubMed
S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015. PubMed
B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity,” European Urology, vol. 67, no. 1, pp. 85–97, Jan. 2015. PubMed
E. R. Plimack, J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes, “Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity,” J. Clin. Oncol., vol. 32, no. 18, pp. 1895–1901, Jun. 2014. PubMed
A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014. PubMed
A. Kutikov, P. Makhov, K. Golovine, D. J. Canter, M. Sirohi, R. Street, J. Simhan, R. G. Uzzo, and V. M. Kolenko, “Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer,” Urology, vol. 78, no. 4, pp. 968.e7–11, Oct. 2011. PubMed
A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011. PubMed
A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010. PubMed
A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009. PubMed
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Chief, Division of Urology and Urologic Oncology
Professor, Department of Surgical Oncology
Kidney, Bladder, and Prostate Cancer TRDG Member
American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member
Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.
I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.
When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.
As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.
Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.
Follow on Twitter: @uretericbud
Dr. Kutikov has authored over 140 peer-reviewed publications. His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks. He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.
Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care. He is a co-founder of several ventures that strive to improve physician education and patient care.
In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.
As part of our work, we explore the role of zinc in development and progression of prostate malignancy. Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.
The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.
In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.
A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed
H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed
M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed
N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed
B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed
S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed
A. Kutikov, H. H. Woo, and J. W. Catto, “Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors,” European Urology, vol. 69, no. 2, pp. 183–185, Feb. 2016. PubMed
A. Kutikov, M. C. Smaldone, R. G. Uzzo, M. Haifler, G. Bratslavsky, and B. C. Leibovich, “Renal Mass Biopsy: Always, Sometimes, or Never?,” European Urology, vol. 70, no. 3, pp. 403–406, Sep. 2016. PubMed
E. R. Plimack, R. L. Dunbrack, T. A. Brennan, M. D. Andrake, Y. Zhou, I. G. Serebriiskii, M. Slifker, K. Alpaugh, E. Dulaimi, N. Palma, J. Hoffman-Censits, M. Bilusic, Y.-N. Wong, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, D. J. McConkey, V. A. Miller, E. A. Golemis, and E. A. Ross, “Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer,” European Urology, vol. 68, no. 6, pp. 959–967, Dec. 2015. PubMed
S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015. PubMed
B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity,” European Urology, vol. 67, no. 1, pp. 85–97, Jan. 2015. PubMed
E. R. Plimack, J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes, “Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity,” J. Clin. Oncol., vol. 32, no. 18, pp. 1895–1901, Jun. 2014. PubMed
A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014. PubMed
A. Kutikov, P. Makhov, K. Golovine, D. J. Canter, M. Sirohi, R. Street, J. Simhan, R. G. Uzzo, and V. M. Kolenko, “Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer,” Urology, vol. 78, no. 4, pp. 968.e7–11, Oct. 2011. PubMed
A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011. PubMed
A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010. PubMed
A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009. PubMed
Dr. Kutikov is a member of the Philadelphia Inquirer's Health Advisory Panel.
You can find some of his selected Inquirer pieces here.
67 PATIENT COMMENTS
-
5.0
July 24, 2020
Best care imaginable/especially in the current situation. I felt safe the entire time and my care was great
-
5.0
July 18, 2020
The quality of care and concern from this Dr and staff is fabulous I have and will recommend Fox Chase to anyone in need of there services. I am cancer free thanks to Dr K and the nurses at Fox Chase
-
5.0
July 17, 2020
dr. Kutilov and his team the greatest people I have ever met they take care of me and safe my life and they know how to put you in good spirit
-
5.0
July 14, 2020
Dr. Kutikove had performed surgery and seems like he had done excellent job. I have been valuing his advise and always willing to talk to my wife, son and daughter.
-
4.4
July 13, 2020
Dr.Kutikov seemed to have a plan in place before talking to me
-
5.0
July 06, 2020
[...] very professional and kind
-
5.0
July 05, 2020
ALWAYS top notch care from doctor, staff, office and hospital.
-
5.0
June 14, 2020
My experience could not have been better. Was excellent. Thank you.
-
5.0
May 26, 2020
It is always a pleasure dealing with Dr Kutakov, he is one of the best . All of the reasons I have done so well recovering from Prostate Cancer are because of his level of expertise and caring. I can never thank him enough and I have recommended Fox Chase to others who have also had a great experience there.
-
5.0
May 24, 2020
Kind and thoughtful
-
5.0
May 14, 2020
tele health visit went OK
-
5.0
May 14, 2020
always a good experience
-
5.0
May 14, 2020
was a tele visit, which was great !
-
5.0
May 11, 2020
Very good excellent.
-
5.0
May 10, 2020
When I was diagnosed back in December with kidney cancer at age 49 I was completely overwhelmed. I was so scarred, but when I was referred to Dr. Kutikov and his team I immediately felt at ease. I had my first visit to discuss my options which was a full nephrectomy. [...]
-
5.0
May 10, 2020
Good experience with Nurse Practioner and Physician on a telehealth appointment.
-
4.5
May 09, 2020
dr kutikov and hiss staff are superb. [...]
-
5.0
May 09, 2020
the care that I need is the best that I can get. Thanks
-
5.0
April 28, 2020
great experience with Dr. Kutikov
-
5.0
April 21, 2020
My visit was a consultation over the phone not in an office atmosphere [...]. I did however receive excellent info from him, found him to be very professional, easy to talk to and respectful. I look forword to meeting him in person and getting started with my care. I would recommend him highly
LOAD MORE